{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:44:31Z","timestamp":1771062271176,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13256-017-1373-5","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T12:00:57Z","timestamp":1501070457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Ludovica","family":"Facchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Stival","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Maria","family":"Roperto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Melosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Materassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Tintori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"de Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iacopo","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"1373_CR1","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","volume":"17","author":"JA Blake-Haskins","year":"2011","unstructured":"Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858\u201366.","journal-title":"Clin Cancer Res"},{"key":"1373_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2012.07.028","volume":"61","author":"J Schmidtko","year":"2013","unstructured":"Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61:289\u201399.","journal-title":"Am J Kidney Dis"},{"key":"1373_CR3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","volume":"20","author":"S Jodele","year":"2014","unstructured":"Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20:518\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1373_CR4","first-page":"30","volume":"5","author":"O Al Ustwani","year":"2014","unstructured":"Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol. 2014;5:30\u20133.","journal-title":"J Gastrointest Oncol"},{"key":"1373_CR5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5009\/gnl.2014.8.1.109","volume":"8","author":"HW Lee","year":"2014","unstructured":"Lee HW, Chung MJ, Kang H, Choi H, Choi YJ, Lee KJ, et al. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the Literature. Gut Liver. 2014;8:109\u201312.","journal-title":"Gut Liver"},{"key":"1373_CR6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","volume":"71","author":"I Glezerman","year":"2009","unstructured":"Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol. 2009;71:130\u20139.","journal-title":"Clin Nephrol"},{"key":"1373_CR7","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","volume":"85","author":"MC Fung","year":"1999","unstructured":"Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85:2023\u201332.","journal-title":"Cancer"},{"key":"1373_CR8","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","volume":"100","author":"BD Humphreys","year":"2004","unstructured":"Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100:2664\u201370.","journal-title":"Cancer"},{"key":"1373_CR9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.22008","volume":"53","author":"GM Milano","year":"2009","unstructured":"Milano GM, Cerri C, Ferruzzi V, Capolsini I, Mastrodicasa E, Genitori L, et al. Congenital glioblastoma. Pediatr Blood Cancer. 2009;53:124\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"1373_CR10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2008.18.4176","volume":"27","author":"L Gandola","year":"2009","unstructured":"Gandola L, Massimino M, Cefalo G, Solero C, Spreafico F, Pecori E, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol. 2009;27:566\u201371.","journal-title":"J Clin Oncol"},{"key":"1373_CR11","unstructured":"UpToDate, Lexicomp. Walters Kluber 2017. Gemcitabine: Pediatric drug information. \nhttp:\/\/www.uptodate.com\/contents\/search\n\n. Accessed 2 Jun 2017."},{"key":"1373_CR12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","volume":"7","author":"JB Lesesne","year":"1989","unstructured":"Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989;7:781\u20139. 13.","journal-title":"J Clin Oncol"},{"key":"1373_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.12202","volume":"161","author":"R Peffault de Latour","year":"2013","unstructured":"Peffault de Latour R, Xhaard A, Freemeaux-Bacchi V, Coppo P, Fischer AM, Helley D, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol. 2013;161:279\u201380.","journal-title":"Br J Haematol"},{"key":"1373_CR14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.2830440115","volume":"44","author":"H Okumura","year":"1993","unstructured":"Okumura H, Nakamura S, Ohtake S, Yoshida T, Kobayashi K, Okabe Y, et al. Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia. Am J Hematol. 1993;44:66\u20137.","journal-title":"Am J Hematol"},{"key":"1373_CR15","first-page":"58","volume":"47","author":"RJ D\u2019Souza","year":"1997","unstructured":"D\u2019Souza RJ, Kwan JT, Hendry BM, Fallon M, Cunningham D. Successful outcome of treating hemolytic uremic syndrome associated with cancer chemotherapy with immunoadsorption. Clin Nephrol. 1997;47:58\u20139.","journal-title":"Clin Nephrol"},{"key":"1373_CR16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1111\/j.1537-2995.2010.02763.x","volume":"50","author":"D Caramazza","year":"2010","unstructured":"Caramazza D, Quintini G, Abbene I, Malato A, Saccullo G, Lo Coco L, et al. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion. 2010;50:2753\u201360.","journal-title":"Transfusion"},{"key":"1373_CR17","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19861001)58:7<1428::AID-CNCR2820580709>3.0.CO;2-J","volume":"58","author":"R Sheldon","year":"1986","unstructured":"Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer. 1986;58:1428\u201336.","journal-title":"Cancer"},{"key":"1373_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000226521","volume":"45","author":"HG Mergenthaler","year":"1988","unstructured":"Mergenthaler HG, Binsack T, Wilmanns W. Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluoruracil-adriamycin-mitomycin C combination chemotherapy. Oncology. 1988;45:11\u20134.","journal-title":"Oncology"},{"key":"1373_CR19","first-page":"266","volume":"12","author":"IC Weitz","year":"2014","unstructured":"Weitz IC. Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis. Clin Adv Hematol Oncol. 2014;12:266\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1373_CR20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1053\/j.ajkd.2010.06.006","volume":"56","author":"RJ Goldberg","year":"2010","unstructured":"Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis. 2010;56:1168\u201374.","journal-title":"Am J Kidney Dis"},{"key":"1373_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40272-016-0194-0","volume":"18","author":"S Y\u00fcksel","year":"2016","unstructured":"Y\u00fcksel S, Evreng\u00fcl H, \u00d6z\u00e7akar ZB, Becerir T, Yal\u00e7\u0131n N, Korkmaz E, et al. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Paediatr Drugs. 2016;18:413\u201320.","journal-title":"Paediatr Drugs"},{"key":"1373_CR22","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169\u201381.","journal-title":"N Engl J Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-017-1373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T12:01:05Z","timestamp":1501070465000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-017-1373-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1186\/s13256-017-1373-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]},"article-number":"209"}}